News & Updates

Show Multimedia Only
Gemcitabine for IR-NMIBC tied to more recurrence vs BCG

Gemcitabine for IR-NMIBC tied to more recurrence vs BCG

06 Jun 2025 byStephen Padilla

Treatment-naive patients with immediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) who received gemcitabine appear to have greater recurrence risk than those given Bacillus Calmette-Guerin (BCG). Both treatments, however, are effective against disease progression.

Gemcitabine for IR-NMIBC tied to more recurrence vs BCG

06 Jun 2025
LHRH analogues vs tE2 patches: Which work best for prostate cancer?

LHRH analogues vs tE2 patches: Which work best for prostate cancer?

02 May 2025
Self-efficacy high among survivors of prostate cancer

Self-efficacy high among survivors of prostate cancer

01 May 2025 byStephen Padilla

Long-term prostate cancer survivors report high levels of self-efficacy, but the contrary is true for subgroups who are facing some challenges, a study presented at EAU 2025 has found.

Self-efficacy high among survivors of prostate cancer

01 May 2025